2871057-47-3
Chemical Structure
BBI-2779
- CAS No.: 2871057-47-3
- Formula:C19H19N7O2
- Molecular Weight:377.40
InChIKey: LCICGMODJWMTPT-TZMCWYRMSA-N
SMILES: COC1=CC=CC(O[C@H]2[C@@H](CC2)N)=C1C3=CC(NC4=NC=C(C#N)N=C4)=NN3
Biological Activity: BBI-2779 is a highly selective, orally active CHK1 inhibitor with a CHK1 IC50 of 0.3 nM. BBI-2779 leverages transcription-replication conflicts on extrachromosomal DNA (ecDNA) to induce synthetic lethality, replication stress, DNA damage and cell death in ecDNA-positive tumor cells. BBI-2779 blocks ecDNA-mediated acquired resistance to targeted therapies and inhibits tumor growth in mouse models of gastric cancer. BBI-2779 is applicable to ecDNA-positive cancer-related research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BBI-2779 | BBI-2779 is a highly selective, orally active CHK1 inhibitor with a CHK1 IC50 of 0.3 nM. BBI-2779 leverages transcription-replication conflicts on extrachromosomal DNA (ecDNA) to induce synthetic lethality, replication stress, DNA damage and cell death in ecDNA-positive tumor cells. BBI-2779 blocks ecDNA-mediated acquired resistance to targeted therapies and inhibits tumor growth in mouse models of gastric cancer. BBI-2779 is applicable to ecDNA-positive cancer-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords